Shanxi C&Y Pharmaceutical Group Stock Forum

The company's low P/S ratio may indicate anticipated continued revenue decline. Its revenue trend lags behind the industry's expected 35% growth in the next year. This low P/S ratio and shrinking revenues could disappoint shareholders in the future.

Despite the lack of revenue growth, market sentiment around the stock is improving, potentially because the market had previously expected weaker results.